Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
48TH FLOOR, CHEUNG KONG CENTER, HONG KONG
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
9 Jun 2026

HUTCHMED (China) Limited securities registration filing

HUTCHMED (China) Limited filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis
Cash and equivalents (USD)$71.33M
Total assets (USD)$1.75B
Total liabilities (USD)$501.84M
Shareholders' equity (USD)$1.24B
Long-term debt (USD)$68.19M
Debt due within a year (USD)$24.97M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance
$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance
$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance
$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance
$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance
$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
QuarterRevenue (USD)Operating incomeNet incomeDiluted EPS (USD)Filed
Q4 2019$53.34M−$38.43M−$29.56MUnavailable20-F · 3 Mar 2020
Q3 2019$49.35M−$35.94M−$31.09MUnavailable6-K · 21 Jan 2020
Q2 2019$50.03M−$35.96M−$25.48MUnavailable6-K · 30 Jul 2019
Q1 2019$52.17M−$36.05M−$19.89M−$0.036-K · 6 Jun 2019
Q4 2018$53.11M−$24.17M−$16.54MUnavailable20-F · 11 Mar 2019
Q3 2018$58.81M−$14.79M−$25.58MUnavailable6-K · 21 Jan 2020

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy
Target: $16.83
14.2% upside potential
📈
Strong Buy
Unavailable
👍
Buy
1
⏸️
Hold
1
📉
Sell
0
2 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 14.00–18.50 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
Verified Insider Transactions Unavailable
Director and insider transaction data is not ingested for this stock yet.

Top Shareholders

Schroder Investment Management Group
1,477,494 shares
0% change
6/30/2026
Allianz Asset Management Gmbh
674,511 shares
-19.459% change
6/30/2026
State Street Corp
313,611 shares
2.881% change
6/30/2026
Aia Group Ltd
291,229 shares
0% change
6/30/2026
M&G Plc
242,791 shares
-4.962% change
6/30/2026
Amundi
204,385 shares
-11.996% change
6/30/2026
Jane Street Group, Llc
194,472 shares
154.165% change
6/30/2026
Renaissance Technologies Llc
130,200 shares
-1.41% change
6/30/2026
Bnp Paribas Financial Markets
104,425 shares
-1.952% change
6/30/2026
Xy Capital Ltd
104,130 shares
115.171% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 19 hours ago